Publication - Advice and guidance

Coronavirus (COVID-19): clinical guidelines for managing systemic anti-cancer therapy (SACT) and radiotherapy (RT) for COVID-19 positive cancer patients

Last updated: 16 November 2021 - see all updates
Directorate: Healthcare Quality and Improvement Directorate
Topic: Health and social care

This document contains guidance for clinical teams on the management of systemic anti-cancer therapy (SACT) and radiotherapy (RT) for Covid-19 positive cancer patients.

This document contains guidance for clinical teams on the management of SACT and RT for patients who test positive for COVID-19. It includes a situation background assessment recommendation (SBAR) report with SACT and RT treatment guidance.

It also contains guidance for the development of standard operating procedures (SOPs) for the safe delivery of SACT to COVID-19 positive patients within cancer centres/ units.

The preparation of these papers has been overseen by the SACT/RT Sub-Group with input and approval from Clinical Cell.

Date guidance came into practice

This guidance is effective from 13 April 2021 and will continue while COVID-19 presents a risk.

First published: 15 April 2021
Last updated: 16 November 2021 - show all updates
All updates: 16 November 2021
Reviewed and still current.

There is a problem

Thanks for your feedback

Was this helpful?

Yes

Your comments

Your feedback helps us to improve this website. Do not give any personal information because we cannot reply to you directly.

Choose a reason for your feedback

Your comments

Your feedback helps us to improve this website. Do not give any personal information because we cannot reply to you directly.

Yes, but

Choose a reason for your feedback

Your comments

Your feedback helps us to improve this website. Do not give any personal information because we cannot reply to you directly.

Information

Date guidance came into practice

There is a problem